Price movement over the last 24 hours
ARK Genomic Revolution ETF vs Autozone Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Autozone Inc trades at $3,072 (market cap $50.16B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | AZO | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $4.35K |
52-Week Low | $23.09 | $2.94K |
Market Cap | — | $50.16B |
Enterprise Value | — | $62.54B |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
AutoZone (AZO) trades at $3,072.64, up 2.07% today, amid a bearish technical signal but strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue has grown steadily to $18.94B in 2025, though net income margins are declining. The company continues aggressive share buybacks and international expansion, with a consensus price target of $3,740.
The outlook is cautiously optimistic, driven by buyback programs and commercial momentum, but risks include competitive pressures and margin compression. With 73% of analysts rating it a Buy, the stock offers value if execution aligns with expansion plans, though investors should monitor same-store sales trends and macroeconomic impacts on discretionary spending.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →